期刊
EMERGING INFECTIOUS DISEASES
卷 17, 期 4, 页码 633-638出版社
CENTERS DISEASE CONTROL
DOI: 10.3201/eid1704.101146
关键词
-
资金
- European Specific Targeted Research Projects Theradpox [018700]
- French agency for cancer research (Association pour la Recherche sur le Cancer)
Myxomatosis in Europe is the result of the release of a South America strain of myxoma virus in 1952. Several attenuated strains with origins in South America or California have since been used as vaccines in the rabbit industry. We sequenced the genome of the SG33 myxoma virus vaccine strain and compared it with those of other myxoma virus strains. We show that SG33 genome carries a large deletion in its right end. Furthermore, our data strongly suggest that the virus isolate from which SG33 is derived results from an in vivo recombination between a wild-type South America (Lausanne) strain and a California MSD-derived strain. These findings raise questions about the use of insufficiently attenuated virus in vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据